Provided by Tiger Trade Technology Pte. Ltd.

OKYO Pharma Limited

1.50
-0.0400-2.60%
Post-market: 1.48-0.0187-1.25%17:51 EDT
Volume:38.55K
Turnover:58.87K
Market Cap:78.72M
PE:-6.25
High:1.56
Open:1.55
Low:1.49
Close:1.54
52wk High:3.20
52wk Low:1.34
Shares:52.48M
Float Shares:28.04M
Volume Ratio:0.55
T/O Rate:0.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2400
EPS(LYR):-0.2400
ROE:-263.78%
ROA:-43.09%
PB:6.38
PE(LYR):-6.25

Loading ...

OKYO Pharma Files Form 3 for Chief Scientific Officer Rajkumar V. Patil

Reuters
·
Jul 30

OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

GlobeNewswire
·
Jul 28

OKYO Pharma Joins BTIG Biotechnology Conference 2026

Reuters
·
Jul 27

OKYO Pharma (NASDAQ:OKYO) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.
·
Jul 27

OKYO Pharma Director Ups Stake Ahead of Planned Phase 3 Neuropathic Corneal Pain Trial

TIPRANKS
·
Jul 24

Okyo Pharma director John Brancaccio acquires 5,000 shares at $1.38

TIPRANKS
·
Jul 24

OKYO Pharma Director Brancaccio Raises Stake to 35,201 Shares After $1.48 Purchase

Reuters
·
Jul 24

Okyo Pharma says Chairman Gabriele Cerrone buys 22,500 shares at $1.45/share

TIPRANKS
·
Jul 23

OKYO Pharma Executive Boosts Shareholding Ahead of Planned Phase 3 NCP Trial

TIPRANKS
·
Jul 22

OKYO Pharma CDO Jacob Lifts Stake to 112,420 Shares with 3,500-share Buy at $1.4

Reuters
·
Jul 22

OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director

GlobeNewswire
·
Jul 22

OKYO Pharma to Present Ophthalmology Pipeline Ahead of Phase 3 Urcosimod Trial

TIPRANKS
·
Jul 21

Okyo Pharma Says Chairman Gabriele Cerrone Boosts Stake to 20.5%

MT Newswires Live
·
Jul 21

OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

GlobeNewswire
·
Jul 21

OKYO Pharma Chairman Raises Stake to 20.51% After Buying 25,000 Shares at $ 1.4

Reuters
·
Jul 21

OKYO Pharma Files Annual Report and Secures Funding for Phase 3 NEPTUNE Trial

TIPRANKS
·
Jul 20

OKYO Pharma Says Cash Position Funds Completion of Neptune Phase 3 Urcosimod Trial

Reuters
·
Jul 20

OKYO Pharma FY26 Net Loss Widens to $8.95 Million

Reuters
·
Jul 20

OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans

GlobeNewswire
·
Jul 20

OKYO Pharma is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jul 13